The NTIS website and supporting ordering systems are undergoing a major upgrade from 8PM on September 25th through approximately October 6. During that time, much of the functionality, including subscription and product ordering, shipping, etc., will not be available. You may call NTIS at 1-800-553-6847 or (703) 605-6000 to place an order but you should expect delayed shipment. Please do NOT include credit card numbers in any email you might send NTIS.
Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website http://www.gpo.gov/fdsys; (3) the federal government Internet portal USA.gov; or (4) a web search conducted using a commercial search engine such as http://www.google.com.
Accession Number ADA564160
Title Role of Receptor Sialylation in the Ovarian Tumor Cell Phenotype.
Publication Date Jun 2012
Media Count 8p
Personal Author S. L. Bellis
Abstract The overarching goal of our research is to define the role of a cancer-associated glycosyltransferase, ST6Gal-I, in regulating the ovarian tumor cell phenotype. In the first year of this pilot project, significant progress has been made toward establishing ST6Gal-I s function in protecting tumor cells from apoptosis. These results establish a new paradigm in apoptotic signaling, particularly given that there is a marked dearth of evidence concerning glycosylation-dependent mechanisms in tumor cell survival. We also show that tumor cells can be sensitized to cisplatin-induced cell death through forced downregulation of ST6Gal-I. Platin drugs represent a first-line treatment for ovarian cancer, therefore therapeutic targeting of ST6Gal-I may hold promise for treating patients that have become chemoresistant. Finally, preliminary results indicate that ST6Gal-I protein is upregulated in human ovarian tumors, implicating ST6Gal-I as a potential new biomarker. In the upcoming year, our studies will focus on elucidating the mechanistic basis by which ST6Gal-I modulates the activity of integrins and death receptors to control tumor cell invasion and apoptosis-resistance.
Keywords Apoptosis
Cells(Biology)
Chemoresistance
Death
Death receptors
Drugs
Galectin
Glycosylation
Invasion
Metastasis
Metastasis disease
Neoplasms
Ovarian cancer
Ovarian cancer cells
Ovaries
Patients
Receptor sites(Physiology)
Sialic acids
Therapy


 
Source Agency Non Paid ADAS
NTIS Subject Category 57E - Clinical Medicine
57B - Biochemistry
Corporate Author Alabama Univ. in Birmingham.
Document Type Technical report
Title Note Annual rept. 15 May 2011-14 May 2012.
NTIS Issue Number 1302
Contract Number W81XWH-11-1-0404

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader